Unicycive Therapeutics, Inc.
Income Statement
| Line Item | Mar 2023 | Sep 2022 |
|---|---|---|
| Revenue | $675.0K | $951.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $3.0M | $4.8M |
| SG&A Expense | $62.0K | $163.0K |
| Operating Income | $-4.2M | $-5.6M |
| Operating Margin | -622.5% | -584.0% |
| Interest Expense | $12.0K | $3.0K |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-14.6M | $-5.6M |
| Net Margin | -2,159.3% | -584.3% |
| EPS (Basic) | $-0.49 | $-0.19 |
| EPS (Diluted) | $-0.49 | $-0.19 |
| Shares Outstanding (Basic) | 30.5M | 30.1M |
| Shares Outstanding (Diluted) | 30.5M | 30.1M |
| Dividends Per Share | — | — |